skip to main content


Title: Proteomics of ovarian cancer: functional insights and clinical applications

In the past decade, there has been an increasing interest in applying proteomics to assist in understanding the pathogenesis of ovarian cancer, elucidating the mechanism of drug resistance, and in the development of biomarkers for early detection of ovarian cancer. Although ovarian cancer is a spectrum of different diseases, the strategies for diagnosis and treatment with surgery and adjuvant therapy are similar across ovarian cancer types, increasing the general applicability of discoveries made through proteomics research. While proteomic experiments face many difficulties which slow the pace of clinical applications, recent advances in proteomic technology contribute significantly to the identification of aberrant proteins and networks which can serve as targets for biomarker development and individualized therapies. This review provides a summary of the literature on proteomics’ contributions to ovarian cancer research and highlights the current issues, future directions, and challenges. In conclusion, we propose that protein-level characterization of primary lesion in ovarian cancer can decipher the mystery of this disease, improve diagnostic tools, and lead to more effective screening programs.
 [1] ;  [2]
  1. Egybiotech for Research and Biotechnology, Alexandria (Egypt); Pacific Northwest National Lab. (PNNL), Richland, WA (United States). Biological Sciences Division
  2. Pacific Northwest National Lab. (PNNL), Richland, WA (United States). Biological Sciences Division
Publication Date:
Report Number(s):
Journal ID: ISSN 0167-7659; 48666; 400412000
Grant/Contract Number:
AC05-76RL01830; 5U24 CA160019-03; ACN12003-001-00000
Accepted Manuscript
Journal Name:
Cancer and Metastasis Reviews
Additional Journal Information:
Journal Volume: 34; Journal Issue: 1; Journal ID: ISSN 0167-7659
Research Org:
Pacific Northwest National Laboratory (PNNL), Richland, WA (US), Environmental Molecular Sciences Laboratory (EMSL)
Sponsoring Org:
USDOE; National Cancer Institute (NCI); National Inst.of Health (NIH)
Country of Publication:
United States
60 APPLIED LIFE SCIENCES; 59 BASIC BIOLOGICAL SCIENCES; Ovarian cancer; Proteomics; Biomarker; Drug resistance; Subtypes; Environmental Molecular Sciences Laboratory
OSTI Identifier: